IRVINE, Calif., April 20, 2011 /PRNewswire/ -- Cardiogenesis Corporation (OTCQB: CGCP) announced that the company will release results for its first quarter ended March 31, 2011 on Wednesday, May 4, 2011. The company added that Paul J. McCormick, its Executive Chairman, and William R. Abbott, its Senior Vice President and Chief Financial Officer, will host an investor conference call that day at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to review the company's financial results and business outlook.
The call is open to all interested investors through a live audio broadcast via the Internet at www.cardiogenesis.com. The call also will be available to investors and analysts by dialing (800) 320-2978 within the U.S. and Canada and (617) 614-4923 from abroad. The passcode is 25661562.
The webcast will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast. A telephonic playback of the conference call will be available beginning at 8:00 p.m. Eastern time on Wednesday, May 4, 2011 and continue through 8:00 p.m. Eastern time on Wednesday, May 11, 2011. The replay can be accessed by calling (888) 286-8010 within the U.S. and Canada and (617) 801-6888 from abroad. The replay passcode is 18993459.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform an FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.
For more information on the company and its products, please visit the Cardiogenesis company website at www.cardiogenesis.com.
SOURCE Cardiogenesis Corporation